Tirzepatide prescribing across the NHS.
Tirzepatide is the largest spend line in English primary care: £625m at list price in the 12 months to April 2026, on 3.2m items, a scale reached within a few years of launch. No molecule page on this site carries more commercial weight right now.
The NHS in England dispensed 3,294,621 prescription items of Tirzepatide in the 12 months to May 2026, across primary care and hospitals.
Spending on Tirzepatide over those 12 months was £673.0m at net ingredient cost, the list price of what was dispensed before any discounts.
Items were up 125.6% on the previous 12 months.
99% of Tirzepatide volume moved through primary care and 1% through hospital pharmacies.
Tirzepatide ranks #3 of 29 chemical substances in Other antidiabetic drugs (BNF 6.1.2.3), by items dispensed.
Among Integrated Care Boards, NHS North East and North Cumbria ICB dispensed the highest volume of Tirzepatide.
Source: NHS Business Services Authority open data (English Prescribing Data and SCMD), OGL v3.0. Items count prescriptions dispensed, not patients treated.
| Month | Items | Spend (NIC) |
|---|---|---|
| May 2026 | 314,985 | £73.0m |
| April 2026 | 311,185 | £71.9m |
| March 2026 | 309,787 | £71.5m |
| February 2026 | 274,847 | £63.1m |
| January 2026 | 292,949 | £67.2m |
| December 2025 | 295,495 | £67.6m |
| November 2025 | 264,380 | £60.1m |
| October 2025 | 280,145 | £63.2m |
| September 2025 | 287,006 | £64.9m |
| August 2025 | 204,546 | £21.6m |
| July 2025 | 244,193 | £26.0m |
| June 2025 | 215,103 | £22.9m |
The same series as the chart, most recent month first. The full monthly history, as CSV, sits behind Apply.
11.8% of its class.
Tirzepatide ranks #3 of 29 chemical substances in Other antidiabetic drugs (BNF 6.1.2.3), by items dispensed in May 2026. The full class league, who's gaining, and the month-by-month share movement sit behind Apply.
Average items by calendar month across the full history, indexed to the annual mean.
Tirzepatide across all 36 ICBs.
Every Integrated Care Board in England, shaded by how much tirzepatide its GPs dispense per head of population. Hover an ICB to name it. The ranked figures for all 36 ICBs, and the drill-down to practice level, are in the full report.
Darker shading marks where Tirzepatide is dispensed most per head of population. Exact figures for every ICB, and the drill-down to practice level, are in the full report.
Zoomed out to the 7 NHS regions.
The same 12 months rolled up to NHS England's seven regions, ranked by intensity.
The teaser view.
Three rows each. The full 36-ICB view, every prescribing organisation, every strength and the hospital picture sit below the fold, behind Apply.
- 1 NHS North East and North Cumbria ICB 200k
- 2 NHS Surrey and Sussex ICB 176k
- 3 NHS Greater Manchester ICB 168k
- – + 33 more. Unlock the full 36-ICB table. Unlock →
- 1 NHS Dorset ICB +251.7%
- 2 NHS Derby and Derbyshire ICB +213.7%
- 3 NHS South East London ICB +182.5%
- – + 33 more. Unlock every ICB, ranked. Unlock →
- 1 Mounjaro KwikPen 5mg/0.6ml inj 2.4ml pre-filled pens 33%
- 2 Mounjaro KwikPen 7.5mg/0.6ml inj 2.4ml pre-filled pens 13%
- 3 Tirzepatide 5mg/0.6ml inj 2.4ml pf dispos dev 12%
- – + 3 more. Unlock every strength and pack. Unlock →
Split of items across NHSBSA primary care and SCMD hospital dispensing.
Prescribing by deprivation.
Items per 1,000 registered patients by deprivation decile (1 = most deprived), practice deprivation weighted by where each practice's patients live. Read the shape rather than the absolute level: the most and least deprived deciles cover far fewer practices, and age structure drives much of the gradient.
The devolved nations.
| Nation | Items · 12 months | Data to |
|---|---|---|
| England | 3.3m | May 2026 |
| Northern Ireland | 70k | May 2026 |
| Scotland | 104k | April 2026 |
| Wales | 188k | April 2026 |
Each nation publishes its own community prescribing data, with different coding and list rules, so read these per-nation rather than as an exact UK total. Sources: NHSBSA (England), Public Health Scotland.
What open data won't tell you about tirzepatide.
Open data does not record why a script was written, so type 2 diabetes and weight-management prescribing sit together in one number. Spend is net ingredient cost, the list price; whatever discount arrangements exist are not visible here.
Asked and answered.
Is tirzepatide prescribing rising or falling in the NHS?
Rising. England dispensed 3,294,621 items of Tirzepatide in the 12 months to May 2026, up 125.6% on the previous 12 months. Items count prescriptions dispensed, not patients treated, so the change can reflect dose and duration shifts as well as patient numbers.
How much does the NHS spend on tirzepatide?
£673.0m at net ingredient cost in the 12 months to May 2026. Net ingredient cost is the list price of the medicine before discounts and rebates; the NHS's final bill, especially for hospital medicines, is usually lower.
Where in England is tirzepatide prescribed most?
By raw volume, NHS North East and North Cumbria ICB dispensed the most tirzepatide in the last 12 months. Raw volume favours the biggest populations; the map on this page shades every ICB by items per head to correct for that.
How up to date is this data?
This page runs to May 2026, the most recent NHSBSA release. Prescribing data publishes roughly six to eight weeks in arrears, and DoseTrend refreshes within 48 hours of each monthly release.
The full breakdown.
Every ICB, every prescribing organisation, every strength, the hospital view, and the monthly briefing PDF. Sample rows shown below with the numbers obscured.
Related pages.
See the full molecule directory, or read about the data and pricing.
Track tirzepatide like this, every month.
£1,500 a month per molecule. Apply and we'll pre-fill Tirzepatide for you.